CA2378324A1 - Adenovirus recombinant - Google Patents

Adenovirus recombinant Download PDF

Info

Publication number
CA2378324A1
CA2378324A1 CA002378324A CA2378324A CA2378324A1 CA 2378324 A1 CA2378324 A1 CA 2378324A1 CA 002378324 A CA002378324 A CA 002378324A CA 2378324 A CA2378324 A CA 2378324A CA 2378324 A1 CA2378324 A1 CA 2378324A1
Authority
CA
Canada
Prior art keywords
fiber
adenovirus
seq
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378324A
Other languages
English (en)
Inventor
Leif Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Got-A-Gene AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902601A external-priority patent/SE9902601D0/xx
Application filed by Individual filed Critical Individual
Publication of CA2378324A1 publication Critical patent/CA2378324A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un adénovirus recombinant de tropisme modifié. Dans un adénovirus, la fibre pentone native composée d'une queue, d'une tige et d'un spicule incluant un motif de trimérisation, a été changée en ce sens que le spicule natif contenant la structure liaison de cellule et le motif de trimérisation natif ont été enlevés et un nouveau ligand liaison de cellule et un motif de trimérisation externe ont été introduits dans la fibre virus. L'invention concerne également l'adénovirus recombinant destiné au traitement de maladies de l'être humain, in vivo ou par des procédés in vitro, ainsi qu'un procédé de sauvetage de fibres adénovirus recombinant dans le génome adénovirus.
CA002378324A 1999-07-06 2000-06-30 Adenovirus recombinant Abandoned CA2378324A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9902601A SE9902601D0 (sv) 1999-07-06 1999-07-06 Recombinant adenovirus
SE9902601-5 1999-07-06
US14363299P 1999-07-14 1999-07-14
US60/143,632 1999-07-14
PCT/SE2000/001390 WO2001002431A1 (fr) 1999-07-06 2000-06-30 Adenovirus recombinant

Publications (1)

Publication Number Publication Date
CA2378324A1 true CA2378324A1 (fr) 2001-01-11

Family

ID=26663617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378324A Abandoned CA2378324A1 (fr) 1999-07-06 2000-06-30 Adenovirus recombinant

Country Status (7)

Country Link
EP (1) EP1196435A1 (fr)
JP (1) JP2003531568A (fr)
KR (1) KR20020092886A (fr)
CN (1) CN1359391A (fr)
AU (1) AU763733B2 (fr)
CA (1) CA2378324A1 (fr)
WO (1) WO2001002431A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104634978A (zh) * 2013-11-13 2015-05-20 长春百克生物科技股份公司 一种分型检测腺病毒中和抗体的方法以及用于分型检测腺病毒中和抗体的试剂盒

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276888A2 (fr) * 2000-04-26 2003-01-22 Crucell Holland B.V. Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
AU2002238537B8 (en) * 2001-02-07 2006-08-24 Wilex Ag Hybridoma cell line G250 and its use for producing monoclonal antibodies
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
EP1524995B1 (fr) 2002-07-01 2011-12-21 Wilex AG Coadministration de cg250 et d'il-2 ou d'ifn-alpha, destinee au traitement de cancers tels que les hypernephromes
CA2601629A1 (fr) * 2004-11-30 2006-06-08 Kiim Pharm Lab. Inc. Medicament anti-vih, polypeptide constituant ledit medicament, gene codant le polypeptide et procede de production du medicament anti-vih
WO2007094653A1 (fr) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Particules adénovirales ayant une protéine s adénovirale chimérique, et utilisation et procédés de production de ces particules
EP2248903A1 (fr) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
CN102775500A (zh) * 2012-08-03 2012-11-14 郑骏年 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3250609A4 (fr) * 2015-01-26 2018-07-11 The University of Chicago Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
EP3390428B1 (fr) 2016-02-23 2019-09-25 Salk Institute for Biological Studies Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
NZ323834A (en) * 1995-11-28 2000-01-28 Genvec Inc Chimeric adenovirus coat protein vectors and methods for gene transfer to cells
JP2001520511A (ja) * 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
BR9908018A (pt) * 1998-02-17 2000-10-24 Uab Research Foundation Adenovìrus modificado contendo uma proteìna de substituição de fibra

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104634978A (zh) * 2013-11-13 2015-05-20 长春百克生物科技股份公司 一种分型检测腺病毒中和抗体的方法以及用于分型检测腺病毒中和抗体的试剂盒

Also Published As

Publication number Publication date
AU763733B2 (en) 2003-07-31
WO2001002431A1 (fr) 2001-01-11
AU6040100A (en) 2001-01-22
KR20020092886A (ko) 2002-12-12
JP2003531568A (ja) 2003-10-28
EP1196435A1 (fr) 2002-04-17
CN1359391A (zh) 2002-07-17

Similar Documents

Publication Publication Date Title
AU763733B2 (en) Recombinant adenovirus
AU698254B2 (en) Chimeric adenoviral fiber protein and methods of using same
Dmitriev et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
AU726544B2 (en) Targeted adenovirus vectors
Belousova et al. Genetically targeted adenovirus vector directed to CD40-expressing cells
AU684220B2 (en) Recombinant adenovirus comprising a chimeric penton base protein
JP2001503250A (ja) 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス
JP2000516098A (ja) 短シャフトアデノウイルスファイバーおよびその用途
JP2001522236A (ja) 改変アデノウイルスファイバーおよび標的アデノウイルス
JPH10501681A (ja) 核酸送達システムならびにその合成および使用方法
US7456008B2 (en) Modified virus comprising one or more non-native polypeptides
JP2001505047A (ja) 高キャパシティーアデノウイルスベクターの開発の促進に使用するためのパッケージング細胞系
AU2002344190B2 (en) Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2007061762A2 (fr) Complexe de transfert de genes non viral
JP2003508057A (ja) 改変アデノウイルスファイバーおよび用途
AU2004238979B2 (en) Broadening adenovirus tropism
JP2000157289A (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクタ―
US20050003548A1 (en) Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
JP2007514429A (ja) 細胞表面に連結され得る物質を連結するためのアダプター
WO2004011489A2 (fr) Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes
CA2237059C (fr) Vecteurs adenoviraux cibles
TW585909B (en) Method for gene transfer into target cells with retrovirus
Medina-Kauwe A Novel Gene Delivery System Targeted to fireast Cancer Cells
Glasgow et al. 124. Characterization of a Chimeric Xeno-Knob Adenovirus Vector for Novel Tropism
JP2002515248A (ja) 出血性腸炎ウイルスのｄｎａ配列、それによりコードされるタンパク質およびその様々な用途

Legal Events

Date Code Title Description
FZDE Dead